Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes

International Journal of Neuropsychopharmacology

Volumn 15, Issue 9, 2012, Pages 1331-1342

  O'Tuathaigh, Colm M P ^a,b   Clarke, Gerard ^c,d   Walsh, Jeremy ^a   Desbonnet, Lieve ^a   Petit, Emilie ^a   O'Leary, Claire ^a   Tighe, Orna ^a   Clarke, Niamh ^a   Karayiorgou, Maria ^e   Gogos, Joseph A ^e   Dinan, Ted G ^c,d   Cryan, John F ^c,d   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cannabinoid; COMT; HPLC analysis; prepulse inhibition; social behaviour; tolcapone

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CATECHOL METHYLTRANSFERASE; DOPAMINE; SEROTONIN; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME POLYMORPHISM; EX VIVO STUDY; GENETICS; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SENSORY GATING; STRESS; WILD TYPE;

ALLELES; ANIMALS; ANXIETY; BENZOPHENONES; BENZOXAZINES; BIOGENIC MONOAMINES; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; ENZYME INHIBITORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; NAPHTHALENES; NITROPHENOLS; PAIN MEASUREMENT; PHENOTYPE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; STARTLE REACTION; SWIMMING;

EID: 84870593059     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001581     Document Type: Article

References (49)

1. Allen NC, Bagade S, McQueen MB, Ioannadis JP, et al. (2008). Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia : the SzGene database. Nature Genetics 40, 827-834.
2. Arguello PA, Jentsch JD (2004). Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology 177, 141-150.
3. Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110-117.
4. Babovic D, O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ et al. (2008). Phenotypic characterization of cognition and social behavior in mice with heterozygous vs. homozygous deletion of catechol-O-methyltransferase. Neuroscience 155, 1021-1029.
5. Barnett JH, Scoriels L, Munafo MR (2008). Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biological Psychiatry 64, 137-144.
6. Baek J, Zheng Y, Darlington CL, Smith PF (2009). The CB1 receptor agonist, WIN 55, 212-2, dose-dependently disrupts object recognition memory in adult rats. Neuroscience Letters 464, 71-73.
7. Boucher AA, Arnold JC, Duffy L, Schofield PR, et al. (2007). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology 192, 325-336.
8. Boucher AA, Hunt GE, Micheau J, Huang X et al. (2011). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology 12, 1-13.
9. Bourin M, Hascoet M(2003). The mouse light/dark box test. European Journal of Pharmacology 463, 55-65.
10. Cannon TD, van Erp TG, Bearden CE, et al. (2003). Early and late neurodevelopmental influences in the prodrome to schizophrenia : contributions of genes, environment, and their interactions. Schizophrenia Bulletin 29, 653-669.
11. Caspi A, Moffitt TE, Cannon M, McClay J, et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a generenvironment interaction. Biological Psychiatry 57, 1117-1127.
12. Costas J, Sanjuan J, Ramos-Rios R, Paz E, et al. (2011). Interaction between COMT haplotypes and cannabis in schizophrenia : a case-only study in two samples from Spain. Schizophrenia Research 127, 22-27.
13. Craddock N, Owen MJ, O'Donovan MC (2006). The catechol-O- methyltransferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Molecular Psychiatry 11, 446-458.
14. Desbonnet L, Garrett L, Clarke G, Bienenstock J, et al. (2008). The probiotic Bifidobacteria infantis : an assessment of potential antidepressant properties in the rat. Journal of Psychiatric Research 43, 164-174.
15. Fatemi SH, Folsom TD (2009). The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 35, 528-548.
16. Giakoumaki SG, Roussos P, Bitsios P (2008). Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 33, 3058-3068.
17. Gogos JA, Morgan M, Luine V, Santha M, et al. (1998). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proceedings of the National Academy of Sciences USA 95, 9991-9996.
18. Haasio K, Huotari M, Nissinen E (2003). Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. Journal of Applied Toxicology 23, 213-219.
19. Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE (2001). Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sciences 68, 1367-1382.
20. Henquet C, Murray R, Linszen D, van Os J (2005). The environment and schizophrenia : the role of cannabis use. Schizophrenia Bulletin 31, 608-612.
21. Henquet C, Rosa A, Krabbendam L, Papiol S, et al. (2006). An experimental study of catechol-O-methyltransferase Val(158)Met moderation of delta-9-tetrahydrocannabinolinduced effects on COMT Val158Met moderation of stressinduced psychosis and cognition. Neuropsychopharmacology 31, 2748-2757.
22. Huotari M, Santha M, Lucas LR, Karayiorgou M, et al. (2002). Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. Journal of Pharmacology and Experimental Therapeutics 303, 1309-1316.
23. Leweke FM, Schneider M (2011). Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia : effects of the atypical antipsychotic quetiapine. International Journal of Neuropsychopharmacology 14, 43-51.
24. Long LE, Chesworth R, Arnold JC, Karl T (2010). A follow-up study: acute behavioural effects of Delta (9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology 211, 277-289.
25. Moore TH, Zammit S, Lingford-Hughes A (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
26. Nadler JJ, Moy SS, Dold G, Trang D, et al. (2004). Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain and Behavior 3, 303-314.
27. Okochi T (2009). Meta-analysis of association between genetic variants in COMT and schizophrenia : an update. Schizophrenia Research 110, 140-148.
28. O'Tuathaigh CMP, Babovic D, O'Meara G, Clifford JJ, et al. (2007). Susceptibility genes for schizophrenia : phenotypic characterisation of mutant models. Neuroscience and Biobehavioural Reviews 31, 60-78.
29. O'Tuathaigh CMP, Kirby BP, Moran PM, Waddington JL, et al. (2010a). Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophrenia Bulletin 36, 271-288.
30. O'Tuathaigh CMP, Harte M, Tighe O, O'Leary C, et al. (2010b). Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice: NMDA-receptor antagonist effects, neurochemistry and brain structure. European Journal of Neuroscience 31, 349-358.
31. O'Tuathaigh CM, Hryniewiecka M, Behan A, Tighe O, et al. (2010c). Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT knockout mice: impact on phenotypes relevant to psychosis. Neuropsychopharmacology 35, 2262-2273.
32. Papaleo F, Crawley JN, Song J, Lipska BK, et al. (2008). Genetic dissection of the role of catechol-Omethyltransferase in cognition and stress reactivity in mice. Journal of Neuroscience 28, 8709-8723.
33. Paterlini M, Zakharenko SS, Lai W-S, Qin J, et al. (2005). Transcriptional and behavioural interaction between 22q11.2 orthologs modulates schizophreniarelated phenotypes in mice. Nature Neuroscience 8, 1586-1594.
34. Pelayo-Teran JM, Perez-Iglesias R, Mata I, Carrasco-Marin E, et al. (2010). Catechol-Omethyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Research 179, 291-296.
35. Powell SB, Zhou X, Geyer MA (2009). Prepulse inhibition and genetic models of schizophrenia. Behavioural Brain Research 204, 282-294.
36. Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, et al. (2009). Sensorimotor gatting depends on polymorphisms of the serotonin-2A receptor and catechol-Omethyltransferase, but not on neuregulin-1 Arg38Gin genotype: a replication study. Biological Psychiatry 66, 614-620.
37. Quednow BB, Wagner M, Mossner R, Maier W, et al. (2010). Sensorimotor gating of schizophrenia patients depends on catechol-O-methyltransferase Val158Met polymorphism. Schizophrenia Bulletin 36, 341-346.
38. Roussos P, Giakoumaki SG, Bitsios P (2009). Tolcapone effects on gating, working memory, and mood interact with synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biological Psychiatry 66, 997-1004.
39. SchneiderM, KochM(2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760-1769.
40. Schneider M, Schomig E, Leweke FM (2008). Acute and chronic cannabinoid treatment differentially affects recognition memory and social behaviour in pubertal and adult rats. Addiction Biology 13, 345-357.
41. Tejedor-Real P, Sahagun M, Biguet NF, Mallet J (2007). Neonatal handling prevents the effect of phencyclidine in an animal model of negative symptoms of schizophrenia. Biological Psychiatry 61, 865-872.
42. Tunbridge EM, Harrison PJ, Weinberger DR (2006). Catechol-O- methyltransferase, cognition, and psychosis: Val158Met and beyond. Biological Psychiatry 60, 141-151.
43. van Os J, Kenis G, Rutten BP (2010). The environment and schizophrenia. Nature 468, 203-212.
44. Waddington JL, Hennessy RJ, O'Tuathaigh CMP, Owoeye O, et al. (2011). Schizophrenia and the lifetime trajectory of psychotic illness : developmental neuroscience and pathobiology, redux. In : Brown AS, Harrison PH (Eds), The Origins of Schizophrenia. New York: Columbia University Press (in press).
45. Walsh J, Tighe O, Lai D, Harvey R, et al. (2010). Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1. Brain Research 1348, 114-119.
46. Wegener N, Koch M (2009). Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Research 1253, 81-91.
47. Yee BK, Chang T, Pietropaolo S, Feldon J (2005). The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behavioural Brain Research 163, 265-276.
48. Yim TT, Hong NS, Ejaredar M, McKenna JE, et al. (2008). Post-training CB1 cannabinoid receptor agonist activation disrupts long-term consolidation of spatial memories in the hippocampus. Neuroscience 151, 929-936.
49. Zammit S, Spurlock G, Williams H, Norton N, et al. (2007). Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia : interactions with tobacco and cannabis use. British Journal of Psychiatry 191, 402-407.